Importance and Management of Non-High-Density Lipoprotein Cholesterol in Dyslipidemia Treatment.

98 The RESPECT-EPA Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy—Statin and Eicosapentaenoic Acid found that icosapentethyl treatment resulted in a numerically lower risk of CV events vs control in patients with chronic CAD on statin therapy, although it did not reach statistical significance. 99 Fibrate monotherapy Fibrates, a class of peroxisome proliferator-activated receptor agonists, are known for their clinical effects on atherogenic dyslipidemia (ie, reducing TGs and elevating HDL-C). 100 The Helsinki Heart Study showed CV risk reduction with gemfibrozil vs placebo in primary prevention individuals with elevated non-HDL-C. 101 Gemfibrozil increased HDL-C and reduced LDL-C, non-HDL-C, and TGs vs placebo.

also in 111,027 other papers